loading

Bristol Myers Squibb Co Borsa (BMY) Ultime notizie

pulisher
Jul 25, 2025

Ex-BMS General Counsel Joins Bausch Health Board - Law360

Jul 25, 2025
pulisher
Jul 25, 2025

Oncology Drugs Market Insights, Competitive Landscape, and Forecast Report 2025-2032 | Immunotherapy Leads Growth in Oncology Market Due to Better Precision and Fewer Side Effects - GlobeNewswire Inc.

Jul 25, 2025
pulisher
Jul 25, 2025

Bristol Myers’ Top Doctor Exits in Midst of Search for New Hit Drug - Bloomberg

Jul 25, 2025
pulisher
Jul 25, 2025

Bristol Myers Squibb Taps AstraZeneca's Star Executive Who Led 150+ Clinical Studies as New CMO - Stock Titan

Jul 25, 2025
pulisher
Jul 24, 2025

What drives Bristol Myers Squibb Company Equity Right stock priceAccelerated wealth expansion - PrintWeekIndia

Jul 24, 2025
pulisher
Jul 24, 2025

Bristol-Myers Squibb’s New Study: A Potential Game-Changer in Multiple Myeloma Treatment - TipRanks

Jul 24, 2025
pulisher
Jul 24, 2025

Bristol Myers Gains 6.3% in a Month: Buy, Sell or Hold the Stock? - The Globe and Mail

Jul 24, 2025
pulisher
Jul 24, 2025

Jim Cramer Praises Lowe's CEO, As For CrowdStrike: 'I'll See You At $1000' - Benzinga

Jul 24, 2025
pulisher
Jul 24, 2025

How Bristol Myers Squibb uses AI to validate drugs before they’re even in the lab - Pharma Voice

Jul 24, 2025
pulisher
Jul 23, 2025

Jim Cramer on Bristol-Myers: “Never Seen it This Cheap” - Insider Monkey

Jul 23, 2025
pulisher
Jul 23, 2025

Dr Reddy's kicks off India big pharma earnings with narrow profit miss - Reuters

Jul 23, 2025
pulisher
Jul 23, 2025

Citi Keeps Their Hold Rating on Bristol-Myers Squibb (BMY) - The Globe and Mail

Jul 23, 2025
pulisher
Jul 23, 2025

Bristol-Myers Squibb’s Promising CELMoD Pipeline and Revenue Growth Potential: Analyst Buy Rating - TipRanks

Jul 23, 2025
pulisher
Jul 22, 2025

Bristol Myers Squibb Company Stock Analysis and ForecastOutstanding stock performance - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Bristol Myers Squibb Application for Psoriatic Arthritis Drug Accepted for Review in Four Regions - PharmTech

Jul 22, 2025
pulisher
Jul 22, 2025

Shareholders in Bristol-Myers Squibb (NYSE:BMY) are in the red if they invested three years ago - simplywall.st

Jul 22, 2025
pulisher
Jul 22, 2025

What drives Bristol Myers Squibb Company stock priceFree Advanced Stock Screener Access - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 21, 2025

What analysts say about Bristol Myers Squibb Company stockExceptional financial outcomes - Autocar Professional

Jul 21, 2025
pulisher
Jul 21, 2025

Lobbying Update: $4,780,000 of BRISTOL-MYERS SQUIBB COMPANY lobbying was just disclosed - Quiver Quantitative

Jul 21, 2025
pulisher
Jul 21, 2025

Bristol-Myers Squibb Company (BMY): All Or Nothing With A Breakthrough Drug, Says Jim Cramer - MSN

Jul 21, 2025
pulisher
Jul 21, 2025

FDA accepts Bristol Myers Squibb’s application for Sotyktu in psoriatic arthritis - Investing.com

Jul 21, 2025
pulisher
Jul 21, 2025

FDA accepts Bristol Myers Squibb’s application for Sotyktu in psoriatic arthritis By Investing.com - Investing.com South Africa

Jul 21, 2025
pulisher
Jul 21, 2025

FDA Review: Bristol Myers' Sotyktu Could Become First TYK2 Inhibitor for Psoriatic Arthritis - Stock Titan

Jul 21, 2025
pulisher
Jul 21, 2025

Layoff Tracker: GSK, Sail, BioNTech Cut Staff for Second Time This Year - BioSpace

Jul 21, 2025
pulisher
Jul 21, 2025

Jim Cramer Reflected on These 17 Stocks - Insider Monkey

Jul 21, 2025
pulisher
Jul 20, 2025

Bristol Myers Squibb Stock (BMY) Opinions on Phase 3 Trial Results - Quiver Quantitative

Jul 20, 2025
pulisher
Jul 20, 2025

What analysts say about Bristol Myers Squibb Company Equity Right stockFree Stock Selection - Autocar Professional

Jul 20, 2025
pulisher
Jul 18, 2025

Why Income Investors Are Watching Bristol-Myers Squibb Company (BMY) in 2025 - Insider Monkey

Jul 18, 2025
pulisher
Jul 18, 2025

Bristol Myers' Drug Flunks Blood Cancer-Associated Anemia Trial - AOL.com

Jul 18, 2025
pulisher
Jul 18, 2025

BMS’s Reblozyl Misses Primary Endpoint In Myelofibrosis Anemia - insights.citeline.com

Jul 18, 2025
pulisher
Jul 18, 2025

Morgan Stanley Maintains a Sell Rating on Bristol-Myers Squibb (BMY), Sets a $34 PT - Insider Monkey

Jul 18, 2025
pulisher
Jul 18, 2025

Pfizer (PFE) and Bristol Myers (BMY) Launch Direct-to-Patient Eliquis Program - Insider Monkey

Jul 18, 2025
pulisher
Jul 18, 2025

Bristol Myers drug fails main goal in cancer-linked anemia trial - Reuters

Jul 18, 2025
pulisher
Jul 18, 2025

Bristol-Myers Squibb stock holds steady as Reblozyl study misses endpoint - Investing.com

Jul 18, 2025
pulisher
Jul 18, 2025

Bristol Myers Squibb Announces Topline Results from Phase 3 INDEPENDENCE Trial for Reblozyl® (luspatercept-aamt) in Adult Patients with Myelofibrosis-Associated Anemia - BioSpace

Jul 18, 2025
pulisher
Jul 18, 2025

Bristol Myers' drug fails main goal in cancer-related anemia trial - Reuters

Jul 18, 2025
pulisher
Jul 18, 2025

Bristol Myers' drug fails main goal in late-stage trial for cancer-related anemia - Reuters

Jul 18, 2025
pulisher
Jul 18, 2025

Bristol Myers late-stage trial for anemia drug fails (BMY) - Seeking Alpha

Jul 18, 2025
pulisher
Jul 18, 2025

Bristol Myers Squibb’s Reblozyl misses primary endpoint in myelofibrosis trial By Investing.com - Investing.com South Africa

Jul 18, 2025
pulisher
Jul 18, 2025

Bristol Myers Squibb’s Reblozyl misses primary endpoint in myelofibrosis trial - Investing.com

Jul 18, 2025
pulisher
Jul 18, 2025

Boomers Get a Big Beautiful Tax Break: 4 Safe Stocks Yielding 5% to Buy Now - 24/7 Wall St.

Jul 18, 2025
pulisher
Jul 18, 2025

BMS, Pfizer take DTC route for blood thinner Eliquis - pharmaphorum

Jul 18, 2025
pulisher
Jul 18, 2025

13 Cheap Stocks Under $50 to Buy Now - Insider Monkey

Jul 18, 2025
pulisher
Jul 17, 2025

Bristol Myers, Pfizer to sell blood thinner Eliquis directly to US patients - Reuters

Jul 17, 2025
pulisher
Jul 17, 2025

Bristol‑Myers Squibb, Pfizer Set To Launch Direct‑To‑Patient Eliquis At 40% Off - Benzinga

Jul 17, 2025
pulisher
Jul 17, 2025

Bristol Myers Squibb and Pfizer Launch Online Discount Program for Eliquis Blood Thinner - geneonline.com

Jul 17, 2025
pulisher
Jul 17, 2025

Major drugmakers offer big discount on blood thinner Eliquis - Fox Business

Jul 17, 2025
pulisher
Jul 17, 2025

Bristol-Myers Squibb: Morgan Stanley highlights catalyst driven idea By Investing.com - Investing.com South Africa

Jul 17, 2025
pulisher
Jul 17, 2025

Bristol-Myers Squibb: Morgan Stanley highlights catalyst driven idea - Investing.com

Jul 17, 2025
pulisher
Jul 17, 2025

BMS/Pfizer Offer Direct-to-Consumer Option for Eliquis - Managed Healthcare Executive

Jul 17, 2025
pulisher
Jul 17, 2025

Bristol Myers, Pfizer to sell blood thinner Eliquis directly to patients - Reuters

Jul 17, 2025
pulisher
Jul 17, 2025

How Bristol Myers Squibb and Pfizer's Direct-to-Patient Eliquis Initiative is Reshaping Anticoagulant Access and Profitability - AInvest

Jul 17, 2025
pulisher
Jul 17, 2025

Drugmakers to Sell Popular Blood Thinner Eliquis at 40% Discount - Bloomberg

Jul 17, 2025
pulisher
Jul 17, 2025

Bristol Myers Squibb and Pfizer Announce Direct-to-Patient Eliquis® (apixaban) Option - BioSpace

Jul 17, 2025
pulisher
Jul 17, 2025

Bristol Myers, Pfizer Slash Eliquis Price by 40% with New Direct-to-Patient Program for Top Blood Thinner - Stock Titan

Jul 17, 2025
pulisher
Jul 16, 2025

BROKERS’ NOTES: Buy Novo Nordisk, sell Bristol Myers Squibb - BusinessLIVE

Jul 16, 2025
pulisher
Jul 16, 2025

Will Increased Expenses Affect Bristol Myers' Performance? - The Globe and Mail

Jul 16, 2025
pulisher
Jul 16, 2025

Key facts about Nik Jhangiani, Diageo's new interim CEO - Reuters

Jul 16, 2025
drug_manufacturers_general SNY
$50.37
price up icon 0.48%
drug_manufacturers_general PFE
$24.79
price down icon 2.21%
$116.20
price up icon 2.65%
$306.58
price down icon 0.64%
drug_manufacturers_general MRK
$84.71
price up icon 0.71%
drug_manufacturers_general NVO
$71.70
price up icon 1.37%
Capitalizzazione:     |  Volume (24 ore):